

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-259US

In Re Application Of: **MEHTA, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,207	1/27/05	TBA	26815	TBA	TBA

Title: **OXZOLIDINONE DERIVATIVES AS ANTIMICROBIALS**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-259US

In Re Application of: **MEHTA, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,207	1/27/05	TBA	26815	TBA	TBA

Title: **OXZOLIDINONE DERIVATIVES AS ANTIMICROBIALS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card: Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa: \_\_\_\_\_)

(Date) \_\_\_\_\_

Signature \_\_\_\_\_

Typed or Printed Name of Person Signing Certificate \_\_\_\_\_

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on March 8, 2006

(Date) \_\_\_\_\_

Signature of Person Mailing Correspondence \_\_\_\_\_

Kim Campbell

Typed or Printed Name of Person Mailing Certificate \_\_\_\_\_

\*This certificate may only be used if paying by deposit account.

William D. Hare  
Signature

Dated: **March 8, 2006**

William D. Hare, Esq.      Reg. No. 44,739  
Customer No. 26815

CC:

<b>INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-259US	Serial No.: 10/523,207
	Applicants: MEHTA <i>et al.</i>	
	Filed: 1/27/2005	Group:

U.S. PATENT DOCUMENTS							
EXAMINER .INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,801,600	1/31/1989	Wang <i>et al.</i>	514	376	
	A2	4,921,869	5/1/1990	Wang <i>et al.</i>	514	376	
	A3	5,254,577	10/19/1993	Carlson <i>et al.</i>	514	376	
	A4	5,547,950	8/20/1996	Hutchinson <i>et al.</i>	514	252	
	A5	5,700,799	12/23/1997	Hutchinson <i>et al.</i>	514	235.8	
	A6	5,719,154	2/17/1998	Tucker <i>et al.</i>	514	252	
	A7	5,736,545	4/7/1998	Gadwood <i>et al.</i>	514	252	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	B1	EP 0 312 000	3/18/1992	EPO	C07D	263/20	
	B2	EP 0 352 781	1/31/1990	EPO	C07D	263/20	
	B3	WO 90/02744	3/22/1990	PCT	C07D	413/04	
	B4	WO 93/09103	5/13/1993	PCT	C07D	263/20	
	B5	WO 93/23384	11/25/1993	PCT	C07D	263/20	
	B6	WO 97/10223	3/20/1997	PCT	C07D	263/20	
	B7	WO 98/01446	1/15/1998	PCT	C07D	413/12	
	B8	WO 98/01447	1/15/1998	PCT	C07D	413/12	
	B9	WO 00/32599	6/8/2000	PCT	C07D	417/10	
	B10	WO 02/06278	1/24/2002	PCT	C07D	413/14	
	B11	WO 03/07870	1/30/2003	PCT	A61K		
	B12	WO 03/08389	1/30/2003	PCT	C07D	241/02	
	B13	WO 2004/014392	2/19/2004	PCT	A61K	31/55	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-259US	Serial No.: 10/523,207
	Applicants: MEHTA <i>et al.</i>	
	Filed: 1/27/2005	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C1	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", <i>Journal of Medicinal Chemistry</i> , <u>32</u> :1673-1681 (1989)	
C2	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The "A" Group", <i>Journal of Medicinal Chemistry</i> , <u>33</u> :2569-2578 (1990)	
C3	Tucker et al., "Piperazinyl Oxazolidinone Antibacterial Agents Containing a Pyridine, Diazene, or Triazene Heteroaromatic Ring", <i>Journal of Medicinal Chemistry</i> , <u>41</u> :3727-3735 (1998)	
C4	Selvakumar et al., "Synthesis of Conformationally Constrained Analogues of Linezolid: Structure-Activity Relationship (SAR) Studies on Selected Novel Tricyclic Oxazolidinones", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :3953-3962 (2002)	
C5	Wang et al., "Chiral Synthesis of DUP 721, a New Antibacterial Agent", <i>Tetrahedron</i> , <u>45</u> (5):1323-1326 (1989)	
C6	Park et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives", <i>Journal of Medicinal Chemistry</i> , <u>35</u> :1156-1165 (1992)	
C7	Gadwood & Shinabarger, "Chapter 12. Progress in the Oxazolidinone Antibacterials", <i>Annual Reports In Medicinal Chemistry</i> , <u>35</u> :135-144 (2000)	
C8	Pae et al., "Synthesis and <i>In Vitro</i> Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , <u>9</u> :2679-2684 (1999)	
C9	Pae et al., "3D QSAR Studies on New Oxazolidinone Antibacterial Agents by Comparative Molecular Field Analysis", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , <u>9</u> :2685-2690 (1990)	
C10	Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, June 28-29, 2001, Amsterdam, The Netherlands	
C11	40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 17-20, 2000, Toronto, Canada, Posters 1822-1834	
C12	41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec. 16-19, 2001, Chicago, USA, Posters 1023, 1040-1051	
C13	Harris et al., "Sequential N-Arylation of Primary Amines as a Route To Alkyldiarylamines", <i>Journal of Organic Chemistry</i> , <u>64</u> :6019-6022 (1999)	
C14	Wolfe and Buchwald, "Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides", <i>Journal of Organic Chemistry</i> , <u>65</u> :1144-1157 (2000)	
C15	Kang et al., "Copper-catalyzed N-Arylation of Aryl Iodides with Benzamides or Nitrogen Heterocycles in the Presence of Ethylenediamine", <i>Synlett</i> , <u>3</u> :427-430 (2002)	
C16	Yu et al., "Synthesis and Antibacterial Activity of Linezolid Analogues", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , <u>12</u> (6):857-859 (March 2002)	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	